193 related articles for article (PubMed ID: 35458546)
1. Novel Compound Inhibitors of HIV-1
Robinson CA; Lyddon TD; Gil HM; Evans DT; Kuzmichev YV; Richard J; Finzi A; Welbourn S; Rasmussen L; Nebane NM; Gupta VV; Ananthan S; Cai Z; Wonderlich ER; Augelli-Szafran CE; Bostwick R; Ptak RG; Schader SM; Johnson MC
Viruses; 2022 Apr; 14(4):. PubMed ID: 35458546
[TBL] [Abstract][Full Text] [Related]
2. βTrCP is Required for HIV-1 Vpu Modulation of CD4, GaLV Env, and BST-2/Tetherin.
Song YE; Cyburt D; Lucas TM; Gregory DA; Lyddon TD; Johnson MC
Viruses; 2018 Oct; 10(10):. PubMed ID: 30347660
[TBL] [Abstract][Full Text] [Related]
3. Vpu downmodulates two distinct targets, tetherin and gibbon ape leukemia virus envelope, through shared features in the Vpu cytoplasmic tail.
Lucas TM; Janaka SK; Stephens EB; Johnson MC
PLoS One; 2012; 7(12):e51741. PubMed ID: 23284757
[TBL] [Abstract][Full Text] [Related]
4. Pseudotyping incompatibility between HIV-1 and gibbon ape leukemia virus Env is modulated by Vpu.
Lucas TM; Lyddon TD; Cannon PM; Johnson MC
J Virol; 2010 Mar; 84(6):2666-74. PubMed ID: 20042505
[TBL] [Abstract][Full Text] [Related]
5. High-Throughput NanoBiT-Based Screening for Inhibitors of HIV-1 Vpu and Host BST-2 Protein Interaction.
Li B; Dong X; Zhang W; Chen T; Yu B; Zhao W; Yang Y; Wang X; Hu Q; Wang X
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502213
[TBL] [Abstract][Full Text] [Related]
6. Sequences in gibbon ape leukemia virus envelope that confer sensitivity to HIV-1 accessory protein Vpu.
Janaka SK; Lucas TM; Johnson MC
J Virol; 2011 Nov; 85(22):11945-54. PubMed ID: 21917962
[TBL] [Abstract][Full Text] [Related]
7. Vpu-dependent block to incorporation of GaLV Env into lentiviral vectors.
Christodoulopoulos I; Droniou-Bonzom ME; Oldenburg JE; Cannon PM
Retrovirology; 2010 Jan; 7():4. PubMed ID: 20102634
[TBL] [Abstract][Full Text] [Related]
8. High-throughput assay to identify inhibitors of Vpu-mediated down-regulation of cell surface BST-2.
Zhang Q; Liu Z; Mi Z; Li X; Jia P; Zhou J; Yin X; You X; Yu L; Guo F; Ma J; Liang C; Cen S
Antiviral Res; 2011 Sep; 91(3):321-9. PubMed ID: 21777622
[TBL] [Abstract][Full Text] [Related]
9. Contribution of the Cytoplasmic Determinants of Vpu to the Expansion of Virus-Containing Compartments in HIV-1-Infected Macrophages.
Leymarie O; Lepont L; Versapuech M; Judith D; Abelanet S; Janvier K; Berlioz-Torrent C
J Virol; 2019 Jun; 93(11):. PubMed ID: 30867316
[TBL] [Abstract][Full Text] [Related]
10. The HIV-1 Vpu viroporin inhibitor BIT225 does not affect Vpu-mediated tetherin antagonism.
Kuhl BD; Cheng V; Donahue DA; Sloan RD; Liang C; Wilkinson J; Wainberg MA
PLoS One; 2011; 6(11):e27660. PubMed ID: 22110710
[TBL] [Abstract][Full Text] [Related]
11. Vpu of a Simian Immunodeficiency Virus Isolated from Greater Spot-Nosed Monkey Antagonizes Human BST-2 via Two AxxxxxxxW Motifs.
Yao W; Yoshida T; Hashimoto S; Takeuchi H; Strebel K; Yamaoka S
J Virol; 2020 Jan; 94(2):. PubMed ID: 31666374
[TBL] [Abstract][Full Text] [Related]
12. HIV-1 accessory protein Vpu internalizes cell-surface BST-2/tetherin through transmembrane interactions leading to lysosomes.
Iwabu Y; Fujita H; Kinomoto M; Kaneko K; Ishizaka Y; Tanaka Y; Sata T; Tokunaga K
J Biol Chem; 2009 Dec; 284(50):35060-72. PubMed ID: 19837671
[TBL] [Abstract][Full Text] [Related]
13. HIV-1 Group P is unable to antagonize human tetherin by Vpu, Env or Nef.
Sauter D; Hué S; Petit SJ; Plantier JC; Towers GJ; Kirchhoff F; Gupta RK
Retrovirology; 2011 Dec; 8():103. PubMed ID: 22171785
[TBL] [Abstract][Full Text] [Related]
14. Vpu-Mediated Counteraction of Tetherin Is a Major Determinant of HIV-1 Interferon Resistance.
Kmiec D; Iyer SS; Stürzel CM; Sauter D; Hahn BH; Kirchhoff F
mBio; 2016 Aug; 7(4):. PubMed ID: 27531907
[TBL] [Abstract][Full Text] [Related]
15. BST-2 Expression Modulates Small CD4-Mimetic Sensitization of HIV-1-Infected Cells to Antibody-Dependent Cellular Cytotoxicity.
Richard J; Prévost J; von Bredow B; Ding S; Brassard N; Medjahed H; Coutu M; Melillo B; Bibollet-Ruche F; Hahn BH; Kaufmann DE; Smith AB; Sodroski J; Sauter D; Kirchhoff F; Gee K; Neil SJ; Evans DT; Finzi A
J Virol; 2017 Jun; 91(11):. PubMed ID: 28331088
[TBL] [Abstract][Full Text] [Related]
16. Functional complementation of a model target to study Vpu sensitivity.
Janaka SK; Faurot J; Johnson MC
PLoS One; 2013; 8(6):e68507. PubMed ID: 23840857
[TBL] [Abstract][Full Text] [Related]
17. Role of the endocytic pathway in the counteraction of BST-2 by human lentiviral pathogens.
Lau D; Kwan W; Guatelli J
J Virol; 2011 Oct; 85(19):9834-46. PubMed ID: 21813615
[TBL] [Abstract][Full Text] [Related]
18. Functional antagonism of rhesus macaque and chimpanzee BST-2 by HIV-1 Vpu is mediated by cytoplasmic domain interactions.
Yoshida T; Koyanagi Y; Strebel K
J Virol; 2013 Dec; 87(24):13825-36. PubMed ID: 24109238
[TBL] [Abstract][Full Text] [Related]
19. Some human immunodeficiency virus type 1 Vpu proteins are able to antagonize macaque BST-2 in vitro and in vivo: Vpu-negative simian-human immunodeficiency viruses are attenuated in vivo.
Shingai M; Yoshida T; Martin MA; Strebel K
J Virol; 2011 Oct; 85(19):9708-15. PubMed ID: 21775449
[TBL] [Abstract][Full Text] [Related]
20. Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/Tetherin via a {beta}TrCP-dependent mechanism.
Douglas JL; Viswanathan K; McCarroll MN; Gustin JK; Früh K; Moses AV
J Virol; 2009 Aug; 83(16):7931-47. PubMed ID: 19515779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
